Gabriel Delgado
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $510 and has fallen 70.2% since, to $152 in 2025.
Across 53 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Redhill Biopharma Inc.$166
- Atricure, Inc.$139
- Johnson & Johnson$115
- Merck$88
- Collegium Pharmaceutical, Inc.$64
- Scilex Pharmaceuticals Inc.$54
- plus $567 from 22 others
What the payments were for
- Food & beverage$1,193100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Redhill Biopharma Inc. | 8 | $166 |
| Atricure, Inc. | 1 | $139 |
| Johnson & Johnson | 4 | $115 |
| Merck | 4 | $88 |
| Collegium Pharmaceutical, Inc. | 3 | $64 |
| Scilex Pharmaceuticals Inc. | 3 | $54 |
| Incyte Corporation | 2 | $53 |
| Nalu Medical, Inc. | 2 | $43 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Pfizer | 2 | $37 |
| EMD Serono, Inc. | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 2 | $35 |
| Amgen | 2 | $35 |
| Coherus Oncology, Inc. | 1 | $30 |
| Seagen Inc. | 2 | $27 |
| Genentech USA, Inc. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| AstraZeneca | 1 | $20 |
| G1 Therapeutics, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Biodelivery Sciences International, Inc. | 1 | $18 |
| Nevro Corp. | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Tersera Therapeutics LLC | 1 | $16 |
| Bristol Myers Squibb | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,193 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 17 | $101 |
Paid to pharmacies, not to this prescriber.
Other family in Miami
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- Estrella Moreno RodriguezMiami$30K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.